{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:14:20Z","timestamp":1784920460280,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Community Health"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10900-022-01112-5","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T01:02:41Z","timestamp":1656118961000},"page":"814-821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older"],"prefix":"10.1007","volume":"47","author":[{"given":"Manuela","family":"Tamburro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9953-7769","authenticated-orcid":false,"given":"Giancarlo","family":"Ripabelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"De Dona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Iafigliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albino","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicandro","family":"Samprati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Santagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Adesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela Anna","family":"Di Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cannizzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela Lucia","family":"Sammarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"1112_CR1","unstructured":"U.S. Food and Drug Administration. (2021). Coronavirus (COVID-19) Update: FDA expands eligibility for COVID-19 vaccine boosters. U.S. Food and Drug Administration. November 19, 2021. Retrieved December 18, 2021, from https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters"},{"key":"1112_CR2","unstructured":"World Health Organization. (2021). Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. World Health Organization. November 26, 2021. Retrieved December 7, 2021, from https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern"},{"issue":"5","key":"1112_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMc2119358","volume":"386","author":"I Nemet","year":"2022","unstructured":"Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N., Erster, O., Cohen, C., Kreiss, Y., Alroy-Preis, S., Regev-Yochay, G., Mendelson, E., & Mandelboim, M. (2022). Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. The New England Journal of Medicine, 386(5), 492\u2013494. https:\/\/doi.org\/10.1056\/NEJMc2119358","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"1112_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10900-021-01039-3","volume":"47","author":"G Ripabelli","year":"2022","unstructured":"Ripabelli, G., Tamburro, M., Buccieri, N., Adesso, C., Caggiano, V., Cannizzaro, F., Di Palma, M. A., Mantuano, G., Montemitro, V. G., Natale, A., Rodio, L., & Sammarco, M. L. (2022). Active surveillance of adverse events in healthcare workers recipients after vaccination with COVID-19 BNT162b2 vaccine (Pfizer-BioNTech, Comirnaty): A cross-sectional study. Journal of Community Health, 47(2), 211\u2013225. https:\/\/doi.org\/10.1007\/s10900-021-01039-3","journal-title":"Journal of Community Health"},{"key":"1112_CR5","unstructured":"European Medicines Agency. (2022). Comirnaty. Summary of product characteristics. January 12, 2022. Retrieved January 21, 2022, from https:\/\/www.ema.europa.eu\/documents\/product-information\/comirnaty-epar-product-information_en.pdf"},{"key":"1112_CR6","unstructured":"European Medicines Agency. (2021). Spikevax (previously COVID-19 Vaccine Moderna). Retrieved December 9, 2021, from https:\/\/www.ema.europa.eu\/documents\/product-information\/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf"},{"issue":"6","key":"1112_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.14740\/jocmr4518","volume":"13","author":"D Vasireddy","year":"2021","unstructured":"Vasireddy, D., Vanaparthy, R., Mohan, G., Malayala, S. V., & Atluri, P. (2021). Review of COVID-19 variants and COVID-19 vaccine efficacy: What the clinician should know? Journal of Clinical Medicine Research, 13(6), 317\u2013325. https:\/\/doi.org\/10.14740\/jocmr4518","journal-title":"Journal of Clinical Medicine Research"},{"issue":"6581","key":"1112_CR8","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1126\/science.abn7591","volume":"375","author":"A Muik","year":"2022","unstructured":"Muik, A., Lui, B. G., Wallisch, A.-K., Bacher, M., M\u00fchl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., G\u00fcimil Garcia, R. C., Poran, A., Shpyro, S., Finlayson, A., Cai, H., Yang, Q., Swanson, K. A., T\u00fcreci, \u00d6., & \u015eahin, U. (2022). Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science, 375(6581), 678\u2013680. https:\/\/doi.org\/10.1126\/science.abn7591","journal-title":"Science"},{"issue":"1","key":"1112_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/22221751.2022.2030200","volume":"11","author":"X Wang","year":"2022","unstructured":"Wang, X., Zhao, X., Song, J., Wu, J., Zhu, Y., Li, M., Cui, Y., Chen, Y., Yang, L., Liu, J., Zhu, H., Jiang, S., & Wang, P. (2022). Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerging Microbes and Infections, 11(1), 477\u2013481. https:\/\/doi.org\/10.1080\/22221751.2022.2030200","journal-title":"Emerging Microbes and Infections"},{"issue":"4","key":"1112_CR10","doi-asserted-by":"publisher","first-page":"6145.e5","DOI":"10.1016\/j.cmi.2021.12.013","volume":"28","author":"A Pierobon","year":"2022","unstructured":"Pierobon, A., Dal Zotto, A., Antico, A., De Antoni, M. E., Vianello, L., Gennari, M., Di Caprio, A., Russo, F., Brambilla, G., & Saugo, M. (2022). Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant in a nursing home 28 weeks after two doses of mRNA anti-Covid-19 vaccines: Evidence of a waning immunity. Clinical Microbiology and Infection, 28(4), 6145.e5-6147.e7. https:\/\/doi.org\/10.1016\/j.cmi.2021.12.013","journal-title":"Clinical Microbiology and Infection"},{"key":"1112_CR11","unstructured":"U.S. Food and Drug Administration. (2021). Vaccines and Related Biological Products Advisory Committee meeting. Application for licensure of a booster dose for COMIRNATY (COVID-19 Vaccine, mRNA). November 17, 2021. Retrieved January 10, 2022, from https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/comirnaty-and-pfizer-biontech-covid-19-vaccine"},{"key":"1112_CR12","unstructured":"U.S. Food and Drug Administration. (2021). Vaccines and related biological products advisory committee meeting. EUA amendment request for a booster dose of the Moderna COVID-19 Vaccine. U.S. Nov 19, 2021. Retrieved Jan 10, 2022, from https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/spikevax-and-moderna-covid-19-vaccine"},{"issue":"7","key":"1112_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/biology10070652","volume":"10","author":"G Cocco","year":"2021","unstructured":"Cocco, G., Delli Pizzi, A., Fabiani, S., Cocco, N., Boccatonda, A., Frisone, A., Scarano, A., & Schiavone, C. (2021). Lymphadenopathy after the anti-COVID-19 Vaccine: Multiparametric ultrasound findings. Biology (Basel), 10(7), 652. https:\/\/doi.org\/10.3390\/biology10070652","journal-title":"Biology (Basel)"},{"issue":"9","key":"1112_CR14","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1592\/phco.28.9.1194","volume":"28","author":"J Studdiford","year":"2008","unstructured":"Studdiford, J., Lamb, K., Horvath, K., Altshuler, M., & Stonehouse, A. (2008). Development of unilateral cervical and supraclavicular lymphadenopathy after human papilloma virus vaccination. Pharmacotherapy, 28(9), 1194\u20131197. https:\/\/doi.org\/10.1592\/phco.28.9.1194","journal-title":"Pharmacotherapy"},{"key":"1112_CR15","volume-title":"Infectious diseases","author":"J Cohen","year":"2017","unstructured":"Cohen, J., Powderly, W. G., & Opal, S. M. (2017). Infectious diseases (4th ed.). Elsevier.","edition":"4"},{"key":"1112_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fgwh.2021.761511","volume":"2","author":"A Vassallo","year":"2021","unstructured":"Vassallo, A., Shajahan, S., Harris, K., Hallam, L., Hockham, C., Womersley, K., Woodward, M., & Sheel, M. (2021). Sex and gender in COVID-19 vaccine research: Substantial evidence gaps remain. Frontiers in Global Women\u2019s Health, 2, 761511. https:\/\/doi.org\/10.3389\/fgwh.2021.761511","journal-title":"Frontiers in Global Women's Health"},{"issue":"5","key":"1112_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/infdis\/jiab584","volume":"225","author":"M Gilboa","year":"2022","unstructured":"Gilboa, M., Mandelboim, M., Indenbaum, V., Lustig, Y., Cohen, C., Rahav, G., Asraf, K., Amit, S., Jaber, H., Nemet, I., Kliker, L., Bar-Haim, E., Mendelson, E., Doolman, R., Rubin, C., Regev-Yochay, G., & Kreiss, Y. (2022). Early immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience. Journal of Infectious Diseases, 225(5), 785\u2013792. https:\/\/doi.org\/10.1093\/infdis\/jiab584","journal-title":"Journal of Infectious Diseases"},{"key":"1112_CR18","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2021-0240","author":"F Rahimi","year":"2021","unstructured":"Rahimi, F., & Bezmin Abadi, A. T. (2021). The third booster vaccination dose against COVID-19: Indication for circulating SARS-CoV-2 variants. Future Virology. https:\/\/doi.org\/10.2217\/fvl-2021-0240","journal-title":"Future Virology"},{"issue":"10318","key":"1112_CR19","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","volume":"398","author":"APS Munro","year":"2021","unstructured":"Munro, A. P. S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Gokani, K., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kwok, J., \u2026 COV-BOOST Study Group. (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, 398(10318), 2258\u20132276. https:\/\/doi.org\/10.1016\/S0140-6736(21)02717-3","journal-title":"Lancet"},{"issue":"12","key":"1112_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.40364","volume":"4","author":"AL Beatty","year":"2021","unstructured":"Beatty, A. L., Peyser, N. D., Butcher, X. E., Cocohoba, J. M., Lin, F., Olgin, J. E., Pletcher, M. J., & Marcus, G. M. (2021). Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Network Open, 4(12), e2140364. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.40364","journal-title":"JAMA Network Open"}],"container-title":["Journal of Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10900-022-01112-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10900-022-01112-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10900-022-01112-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T07:13:51Z","timestamp":1663226031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10900-022-01112-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1007\/s10900-022-01112-5","relation":{},"ISSN":["0094-5145","1573-3610"],"issn-type":[{"value":"0094-5145","type":"print"},{"value":"1573-3610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"assertion":[{"value":"31 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not requested, as no experimental procedure was applied in this study, and information provided by participants after signing an informed consent were anonymous.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All the study participants signed an informed consent agreeing to provide data and availability for the survey.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The Authors provide the consent for publication data or figure in the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}